Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized-controlled Study of PD-1 Inhibitor Combined With Local Therapy in Patients With Oligometastatic Esophageal Squamous Cell Carcinoma

NCT06190782 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06190782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06190782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized-controlled Study of PD-1 Inhibitor Combined With Local Therapy in Patients With Oligometastatic Esophageal Squamous Cell Carcinoma
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Recruiting
Start date
September 27, 2022
Completion date
September 27, 2027
Enrollment
354 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous cell carcinoma, oligometastatic disease, radiotherapy